Angelman syndrome
| 2 min read
Phase 3 NEPTUNE trial of OV101 for treatment of Angelman syndrome failed to meet primary endpoint
Page 1 of 1 - 1 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Journeying through cells' spatial dimensions
Spatial biology adds a new layer of knowledge to unsolved biological questions.
A Technology Guide for AI-Enabled Drug Discovery
Learn practical strategies for using artificial intelligence to find the best drug candidate.
Achieving bioanalytical precision and control
Advanced LIMS software helps researchers reliably manage complex bioanalytical workflows and data.
